Morphine, Methamphetamine, and Ketamine Combined Detection Kit

In recent years, the global demand for rapid, accurate, and non-invasive diagnostic tools for detecting psychoactive substances (such as morphine, methamphetamine, and ketamine) has grown significantly. These substances pose severe threats to public health, workplace safety, and social order—from increasing rates of substance use disorders to rising incidents of impaired driving and workplace accidents. Traditional detection methods, such as urine or blood testing, often face limitations: urine testing requires invasive sample collection (which may raise privacy concerns) and longer processing times, while blood testing demands professional medical personnel and specialized equipment, making it unsuitable for on-site or rapid screening scenarios.
To address these gaps, the development of saliva-based in vitro diagnostic reagents has become a key focus in the diagnostic industry. Saliva samples offer unique advantages: they can be collected non-invasively, without the need for specialized training, and the collection process is quick (typically taking less than 2 minutes), minimizing user discomfort and reducing the risk of sample tampering. Additionally, saliva testing allows for the detection of recent substance use (usually within the past 24–48 hours), making it ideal for real-time screening in settings like workplaces, law enforcement checkpoints, and clinical preliminary assessments.
The Combination Reagent (Cat.No: GI-0093) is developed in response to this market need, leveraging the colloidal gold method—a well-established and widely validated technology in rapid diagnostic testing (RDT). The colloidal gold method is favored for its simplicity, speed, and high specificity: it uses gold nanoparticles conjugated to specific antibodies to bind target analytes (morphine, methamphetamine, ketamine) in saliva, producing visible test lines that can be interpreted with the naked eye. This technology eliminates the need for complex laboratory equipment, enabling on-site testing and delivering results in 5–10 minutes—critical for time-sensitive scenarios where immediate decisions (e.g., whether to conduct further confirmatory testing) are required.
Beyond basic detection, this reagent also supports public health initiatives: it serves as a cost-effective primary screening tool, helping healthcare providers, law enforcement agencies, and workplace safety teams triage cases efficiently. By reducing the number of samples that need to be sent for expensive confirmatory testing (e.g., gas chromatography-mass spectrometry, GC-MS), it lowers overall testing costs while maintaining high accuracy—aligning with global efforts to improve access to substance use monitoring tools.